{"id":"hif2a","name":"HIF-2α","symbol":"EPAS1","route":"/targets/hif2a/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3374","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000116016","uniprot":"https://www.uniprot.org/uniprotkb/Q99814/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q99814","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1744522","open-targets":"https://platform.opentargets.org/target/ENSG00000116016","civic":"https://civicdb.org/genes/2034/summary","oncokb":"https://www.oncokb.org/gene/EPAS1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=EPAS1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=EPAS1","depmap":"https://depmap.org/portal/gene/EPAS1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000116016-EPAS1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2034","omim":"https://www.omim.org/entry/603349"}],"products":[{"id":"belzutifan","name":"Belzutifan","status":"approved","modality":"Small-molecule HIF-2α inhibitor","route":"/drugs/belzutifan/"}],"trials":[{"id":"nct04586231","name":"LITESPARK-011","nct":"NCT04586231","phase":"3","status":"positive"},{"id":"litespark-012","name":"LITESPARK-012","nct":"NCT04736706","phase":"3","status":"negative"},{"id":"litespark-022","name":"LITESPARK-022","nct":"NCT05239728","phase":"3","status":"positive"},{"id":"litespark-005","name":"LITESPARK-005","nct":"NCT04195750","phase":"3","status":"positive"},{"id":"nct05899049","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","nct":"NCT05899049","phase":"3","status":"active"},{"id":"nct07405164","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","nct":"NCT07405164","phase":"3","status":"recruiting"},{"id":"nct04489771","name":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","nct":"NCT04489771","phase":"2","status":"active"},{"id":"nct03634540","name":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","nct":"NCT03634540","phase":"2","status":"active"},{"id":"nct04924075","name":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL","nct":"NCT04924075","phase":"2","status":"recruiting"},{"id":"nct04976634","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","nct":"NCT04976634","phase":"2","status":"active"},{"id":"nct06428396","name":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","nct":"NCT06428396","phase":"2","status":"active"},{"id":"nct05468697","name":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6","nct":"NCT05468697","phase":"1/2","status":"active"},{"id":"nct04626479","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","nct":"NCT04626479","phase":"1/2","status":"active"},{"id":"nct04626518","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","nct":"NCT04626518","phase":"1/2","status":"active"},{"id":"nct07049926","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","nct":"NCT07049926","phase":"1/2","status":"recruiting"}],"pathways":["nutrient-competition-tme","renal-cell-carcinoma-signalling","angiogenic-switch","pre-metastatic-niche","ubiquitin-proteasome-system","vegf-angiogenesis","hif-vhl"],"companies":["merck"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}